- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02316808
Cholesterol-lowering Effects of Plant Stanol Ester
December 19, 2014 updated by: Raisio Group
Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented.
LDL-cholesterol lowering efficacy of the ingredient administered in a smoothie is less well known.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
91
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- total cholesterol concentration ≥ 200 mg/dL and < 300 mg/dL, and or LDL-C concentration ≥ 130 mg/dL and < 180 mg/dL
- were willing to consume control or plant stanol ester smoothie drinks two bottles per day immediately after a meal for four weeks,
- reachable by phone
- willing to declare written informed consent
- agreed in accordance with data protective stipulations and readiness to participate in the trial and to adhere to the study conditions.
Exclusion Criteria:
- Pregnant women
- obese
- diabetic subjects or subjects with random plasma glucose concentration > 200 mg/dL
- hyperthyroidism, a history of metabolic, endocrine and kidney disorders
- acute or chronic severe diseases possibly interfering with the evaluation of the outcome of the clinical trial (such as AIDS, tumor diseases, malignant hypertension, cardiac insufficiency according to NYHA III-IV)
- taking lipid-lowering medication or other medications likely to affect lipid metabolism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo smoothie
|
Smoothie that contains placebo
|
|
Experimental: Plant stanol ester smoothie
|
Smoothie that contains plant stanol ester
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change (proportional) in LDL-C from baseline up to 4-weeks after plant stanol ester smoothie drink consumption.
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
December 10, 2014
First Submitted That Met QC Criteria
December 10, 2014
First Posted (Estimate)
December 15, 2014
Study Record Updates
Last Update Posted (Estimate)
December 23, 2014
Last Update Submitted That Met QC Criteria
December 19, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCL_2011_Kal
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemias
-
IlDong Pharmaceutical Co LtdCompletedMixed DyslipidemiasKorea, Republic of
-
Orient Pharma Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed DyslipidemiasTaiwan, Australia, New Zealand
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruiting
-
U.G.A. NutraceuticalsNot yet recruiting
-
Shandong Suncadia Medicine Co., Ltd.RecruitingHyperlipidemiasChina
-
NUR International UniversityCompletedDyslipidaemiaPakistan
-
Riphah International UniversityCompleted
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Salubris (Chengdu) Biotechnology Co., Ltd.CompletedHyperlipidemiasChina
-
Riphah International UniversityCompleted
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States